Tina Flatau

Tina Flatau has extensive work experience in the biotech and pharmaceutical industries. Tina currently serves as the Chief Business Officer at Sixfold Bioscience since December 2021. Prior to this, Tina held various roles at different organizations. From 2017 onwards, they were a Trustee for Action Duchenne, where they focused on research and development and liaised with life science industry developers. Tina also worked as an R&D consultant at Leiden for a year, starting in 2009. Tina has held multiple management positions, including Managing Director at aTen Therapeutics Ltd from 2016 to 2019 and Managing Director & Advisory at MEDANNEX LIMITED & OncoBioPharm Ltd from 2016 to 2020. In their role as VP Alliances and Project Management at Prosensa Therapeutics B.V., Tina played a significant role in the company's IPO on NASDAQ in 2013. Additionally, they worked as an Advisor at Ipsat Therapies in Helsinki from 2008 to 2009 and as an eDMS Project Leader at MedImmune from 2005 to 2008. Tina's career began as a Transformation Leader at UCB Celltech from 2005 to 2007. Overall, Tina Flatau has a diverse background in R&D operations, biotech growth-phase, and business development, contributing to the success of various organizations.

Tina Flatau obtained their education from two different institutions. Tina attended Chelsea School of Pharmacy from 1981 to 1984, where they pursued a degree in Pharmacy and pharmacology and graduated with a B Pharm class I. Following this, Tina Flatau pursued further education at King's College London from 1985 to 1989, where they obtained a PhD in the fields of Pharmaceutics, Pharmacology, and Pharmacy.